MGNX Macrogenics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MGNX

Price (delayed)

$15.62

Market cap

$975.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.15

Enterprise value

$908.2M

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its ...

Highlights
MGNX's debt is down by 2.5% year-on-year
The EPS has plunged by 119% from the previous quarter but it has soared by 92% YoY
MGNX's net income has shrunk by 118% QoQ but it has soared by 92% YoY
The gross profit has plunged by 65% YoY and by 55% from the previous quarter
The revenue has shrunk by 61% YoY and by 51% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.macrogenics.com
Peers: XNCR GILD MRK PFE

Key stats

What are the main financial stats of MGNX
Market
Shares outstanding
62.43M
Market cap
$975.19M
Enterprise value
$908.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.35
Price to sales (P/S)
16.47
EV/EBIT
N/A
EV/EBITDA
164.95
EV/Sales
15.46
Earnings
Revenue
$58.75M
EBIT
-$7.63M
EBITDA
$5.51M
Free cash flow
-$79.91M
Per share
EPS
-$0.15
Free cash flow per share
-$1.29
Book value per share
$2.46
Revenue per share
$0.95
TBVPS
$4.82
Balance sheet
Total assets
$298.42M
Total liabilities
$145.81M
Debt
$33.97M
Equity
$152.61M
Working capital
$195.23M
Liquidity
Debt to equity
0.22
Current ratio
4.48
Quick ratio
4.28
Net debt/EBITDA
-12.17
Margins
EBITDA margin
9.4%
Gross margin
86%
Net margin
-15.4%
Operating margin
-286.4%
Efficiency
Return on assets
-2.8%
Return on equity
-5.8%
Return on invested capital
-3.8%
Return on capital employed
-3.1%
Return on sales
-13%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MGNX stock price

How has the Macrogenics stock price performed over time
Intraday
-2.8%
1 week
-10.95%
1 month
0.26%
1 year
128.7%
YTD
62.37%
QTD
6.11%

Financial performance

How have Macrogenics's revenue and profit performed over time
Revenue
$58.75M
Gross profit
$50.53M
Operating income
-$168.24M
Net income
-$9.06M
Gross margin
86%
Net margin
-15.4%
MGNX's net margin has dropped by 137% since the previous quarter but it has surged by 80% year-on-year
MGNX's net income has shrunk by 118% QoQ but it has soared by 92% YoY
The gross profit has plunged by 65% YoY and by 55% from the previous quarter
The revenue has shrunk by 61% YoY and by 51% QoQ

Growth

What is Macrogenics's growth rate over time

Valuation

What is Macrogenics stock price valuation
P/E
N/A
P/B
6.35
P/S
16.47
EV/EBIT
N/A
EV/EBITDA
164.95
EV/Sales
15.46
The EPS has plunged by 119% from the previous quarter but it has soared by 92% YoY
The P/B is 133% above the last 4 quarters average of 2.8 and 98% above the 5-year quarterly average of 3.3
Macrogenics's equity has decreased by 21% QoQ but it has increased by 7% YoY
The price to sales (P/S) is 88% higher than the 5-year quarterly average of 9.0
The revenue has shrunk by 61% YoY and by 51% QoQ

Efficiency

How efficient is Macrogenics business performance
The ROS has plunged by 131% from the previous quarter but it has soared by 84% YoY
MGNX's return on equity has dropped by 118% since the previous quarter but it has surged by 93% year-on-year
MGNX's ROA has plunged by 118% from the previous quarter but it has soared by 94% YoY
MGNX's ROIC has shrunk by 115% QoQ but it has soared by 95% YoY

Dividends

What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MGNX.

Financial health

How did Macrogenics financials performed over time
The total assets is 105% more than the total liabilities
The quick ratio fell by 22% QoQ
MGNX's current ratio is down by 21% since the previous quarter
MGNX's debt is 78% smaller than its equity
The debt to equity is up by 22% since the previous quarter but it has declined by 12% year-on-year
Macrogenics's equity has decreased by 21% QoQ but it has increased by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.